Another EGFR antagonist, panitumumab, has also been approved by the FDA for wild-type RAS metastatic colorectal cancer in combination with FOLFOX as a first-line treatment [72] and as a monotherapy after chemotherapy-derived disease progression. Here, EGFR is linked to metastatic colorectal cancer.